MIAMI--( / ) January 28, 2020 -- American Intermodal Management (AIM), a U.S.-based marine chassis lessor and a portfolio company of I Squared Capital, has signed an agreement to merge with FlexiVan Leasing, the third largest marine chassis provider in the U.S., owned by Castle & Cooke. I Squared Capital will assume a controlling interest in FlexiVan with Castle & Cooke maintaining a minority interest in the combined business. FlexiVan is one of the three leading companies in the sector with over 60 years of operating history, 300 employees, over 120,000 chassis and an expansive nationwide footprint that will open AIM’s technology-enabled products to new customers across the U.S.
“I Squared Capital is expanding its global presence across the transportation and logistics value chain with approximately $2.2 billion of equity capital committed across North America, Europe and Asia. We are now a leader in trailer and chassis leasing across Europe, Canada and the U.S. as well as the largest private owner of highways in India,” said Adil Rahmathulla, Chairman of the AIM Board and Managing Partner of I Squared Capital. “This is our fifth acquisition in the transport and logistics sector in the last six months and a key milestone as we expand our presence in the U.S. market.”
Formed as a logistics platform by I Squared Capital in 2016, AIM has grown into a leading chassis lessor providing GPS-enabled services to retailers, logistics companies and shipping lines in the U.S. intermodal supply chain. AIM’s innovative technology solutions complement the deep experience and relationships that FlexiVan has established over many years. The combination will allow AIM to deploy its innovative, technology-enabled model on a national scale while maintaining FlexiVan’s established offerings and levels of service.
Evercore served as the financial advisor and White & Case served as legal counsel to I Squared Capital. Citigroup Global Markets Inc. and MUFG Union Bank, N.A. are providing financing.
About FlexiVan Leasing, Inc.
FlexiVan has been a leader in intermodal chassis leasing services in North America since mid-1960s. It manages over 120,000 units in over 100 active locations across the country and has nine owned and operated service centers providing easy access to chassis maintenance services. Leasing options range from chassis pool user agreements and managed fleets, to short- and long-term contracts with motor carriers, logistics providers, ocean carriers and beneficial cargo owners. Meanwhile, to facilitate the daily leasing and dispatching process, FlexiVan per diem rentals are supported by FlexiVan’s streamlined ChassisNow.com booking system. Professional, reliable and cost-effective transportation solutions - Experience Delivered.
About American Intermodal Management, LLC.
AIM is a chassis leasing platform that owns and leases marine chassis to customers that transport marine containers between ports, rail ramps, and distribution centers in the United States. AIM was formed in June 2016 in response to strong industry demand desiring alternatives for chassis provisioning, and asset management across the U.S. The AIM business model combines integrity, proactive-disciplined management processes, high quality assets, innovative technology application, and a passion for excellence to achieve maximum value creation. AIM has experienced significant growth since inception with a fleet of more than 12,000 new chassis equipped with GPS and led by industry veterans.
About I Squared Capital:
I Squared Capital is an independent global infrastructure investment manager focusing on energy, utilities, telecom, transport and social infrastructure in the Americas, Europe and Asia. The firm has offices in Hong Kong, London, Miami, New Delhi, New York and Singapore.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SAN DIEGO & PENNINGTON, N.J.--( / ) February 03, 2020 -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or 일본성인 엠팍 “OncoSec”), a company developing late-stage intratumoral 벗방 차니커뮤니티 cancer immunotherapies, today issued the following statement to its shareholders related to the upcoming Special Meeting to vote on the proposed strategic investment by and partnership (the “CGP/Sirtex Transaction”) with Grand Decade JAVBUS SANLimited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare JAVBUS SANLimited (“CGP”), and its U.S. affiliate, Sirtex Medical US Holdings, Inc. (“Sirtex”):
As we near the end of a long 일본성인 스포업 and contentious proxy 벗방 멀티맨 fight, we want 일본성인 to urge shareholders to look back at 비나한인 Asbasic facts about this vote and the essential 벗방 스포츠중계해골TV 일본성인 스포츠중계해골TV benefits 벗방 아빠벌토렌트 of 투카닷컴 AsCGP/Sirtex Transaction.
? The $30 million 일본성인 텀블러야동 in financing OncoSec would receive through the CGP/Sirtex Transaction is urgently needed 벗방 조교뒤치기 and is the best available option for the Company and you, 벗방 일본성인 our 벗방 부달 우크렐레 벚꽃엔딩 ?
· Eliminates the need 토렌트왈 ·raise capital in a 벗방 CUTSCENES very challenging biotech market for the 벗방 툰코 foreseeable 일본성인 9알바 future.
· Creates 코끼리TV ·key new biopharma partnership 일본성인 미소알바 with two established biopharma companies, CGP 일본성인 보노툰 and 일본성인 캔디알바 Sirtex. 벗방
슈어코리아 ?벗방 에이툰 At $2.50 per share, the CGP/Sirtex Transaction represents an 일본성인 만냥 approximately 25% premium over the average share price during 일본성인 러브나인 the 20 days 벗방 김군토이샵 prior 일본성인 to announcement 최신야동 ?the 벗방 밥툰 transaction on October 10, 2019.
? 한국성인영화 ?and 벗방 씨알케어 Sirtex would get three seats on the Company’s nine-person Board of Directors (the “Board”)?this is not 벗방 툰나라 control 일본성인 드라마다시보기 (unlike 하프라인 ?offer made 일본성인 SinkTV by Alpha Holdings, Inc. (“Alpha”) described below).
Back to the Basics: Alpha’s Offer 벅스클럽 BackGive 일본성인 라라티비 Alpha Control of the Company Before 벗방 마이비누 Alpha Provides a Single Cent of Much-Needed Financing
? Institutional Shareholder Services Inc. commented: “(T)he company has 일본성인 SEXS made a compelling case that 벗방 먹튀회담 the financing 벗방 토토구조대 is necessary and urgent…The proposed transaction also offers the advantage of a 발기력강화 ?partner with global experience. As such, support for 일본성인 pornvideo the proposal is warranted.”
? Glass, Lewis & Co. commented: “[W]e ultimately believe the 벗방 먹튀sos board has reasonably established that the current financing proposal is likely to be 벗방 the best 홍대 유동진 ?most certain alternative 일본성인 DIEHD available 벗방 lovesex to [OncoSec] at this time.”
? For those of 벗방 성인방송 you who have voted on the WHITE proxy card - thank 일본성인 you! You 일본성인 픽스터김선수 do 적각동성인게임장 ?need to take any further action. 일본성인
? If you want 벗방 야한영화다운 일본성인 야한영화다운 your vote to count - whether you support the CGP/Sirtex Transaction 벗방 TPRTM or not - vote omWAEQ ?the WHITE proxy card. Alpha 일본성인 송마담 has said they might not submit 일본성인 페티시스타킹 votes received on their blue proxy card if they don’t like the potential results.
? 일본성인 필고 You deserve a 벗방 야한영화사이트 fair meeting where 벗방 비나한인 your 일본성인 섹스마스터 vote 북산면고스톱 ?
New York, NY 여캠방 New벗방 섹스비디오 일본성인 섹스비디오
About 벗방 섹스 코코토렌트 About벗방 GIRLS4U 일본성인 GIRLS4U
CGP is a public company listed on the Hong Kong stock exchange 일본성인 야한거 with a market capitalization of approximately $2.1 billion USD. 섹스방법 CGPdevelops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations. CGP currently distributes its products to approximately 6,000 hospitals and approximately 30,000 pharmacies and has a sales team of more than 2,000 employees. CGP also has significant experience in R&D and product commercialization in China. Such experience dealing with the relevant Chinese regulatory 이헨타이 CGPmakes CGP an ideal strategic 벗방 야한누드 partner for OncoSec as it looks to gain regulatory approval to introduce TAVO™ 벗방 야덩 to the Chinese market. For more information, visit
About 벗방 성인플래시 일본성인 성인플래시 이헨타이 About벗방 에로 일본성인 에로
Sirtex is a global healthcare business company with offices in the U.S., Australia, Europe and Asia, working to 이헨타이 Sirtexoutcomes in people with cancer. Sirtex’s current lead product 벗방 섹스하는동영상 is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients 티티알바 Sirtexliver cancer at 일본성인 성인채팅 more than 1,000 medical centers in over 40 countries. Sirtex’s global focus on drug development makes it a natural partner 일본성인 에로영화 for the Company as it looks to develop and introduce 벗방 TAVO™ into markets around the world. For more information, 일본성인 일본AV visit
OncoSec Medical Incorporated (the “Company,” 일본성인 야한것 “OncoSec,” “we” or “our”) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body‘s immune system to target and attack cancer. OncoSec’s lead immunotherapy investigational product candidate 남성클리닉 OncoSecTAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, 벗방 성인망가 enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVOTM as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great 홍연실화보 OncoSecmedical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVOTM have demonstrated a local immune response, 야동카트 OncoSecsubsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVOTM, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit
SIR-Spheres® 원당동성인게임장 SIR-Spheres®a registered trademark of Sirtex 벗방 Medical US 일본성인 나체 Holdings, Inc. 벗방
GJCZlJ Risk일본성인 Factors 일본성인 섹시녀 and 벗방 성인동영상사이트 Forward Looking 벗방 Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company’s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company’s control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act 벗방 밤고수 of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission (“SEC”). In particular, you should be aware that the CGP/Sirtex Transaction may not close or may close on materially different terms, that Alpha may succeed in obtaining the relief it seeks in its litigation against the Company, in whole or in part, even though the Company believes that Alpha’s litigation is entirely without merit and that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected 일본성인 토스트토렌트 safety 동내면고스톱 Thisand the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC’s website ), as well as other factors described from time to time in the Company’s filings with the SEC.
View source 일본성인 풀밤 version on businesswire.com:Korea xxx Viewdistributes 티티알바 Viewnews across every 일본성인 오피클럽 media channels 벗방 네이버밤 through 토즐사 Viewindustry’s 벗방 오피가자 largest press 벗방 밤싸 release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.